Although the involvement of the IL-6R/STAT3 signaling pathway in EOC has been explored with regard to tumor progression and chemoresistance [16, 17, 25, 32–34], the use of antibodies (siltuximab and tocilizumab) targeting this signaling pathway has not generated clear clinical relevance [32, 33, 35]. The gene discussed is IL6R; the disease is neoplasm.